Out-of-Pocket Expenses in Patients with Psoriasis: A Study from a Tertiary Care Hospital in North India

BACKGROUND: Chronic inflammatory skin diseases, like psoriasis, have a significant financial burden on patients. Developing countries could have a more severe impact due to low per capita income and low penetration of health insurance. AIM AND OBJECTIVES: To evaluate the out-of-pocket (OOP) expenses of psoriasis patients and compare them between mild-moderate cases and severe cases. PATIENTS AND METHODS: The study involved psoriasis patients who were categorized into two groups based on the disease severity. The OOP expenses were calculated for the past four weeks. Inpatient versus outpatient management costs were also compared. RESULTS: The mean monthly OOP expenditure on treatment was significantly higher for the severe disease group [₹7087 ± 9021 ($85.45 ± 108.77/€78.09 ± 99.40)] than for the mild-moderate group [₹1871 ± 2138 ($22.56 ± 25.78/€20.61 ± 23.55) ( P = 0.001)]. In the severe disease group, OOP expenditure was notably higher than the mild-moderate group, primarily for medicines [₹4622 ± 7134 ($55.73 ± 86.02/€50.93 ± 78.61) vs ₹657.7 ± 534.9 ($7.93 ± 6.45/€7.24 ± 5.89) ( P = 0.001)] and diagnostics [₹1235 ± 1492 ($14.89 ± 17.99/€13.60 ± 16.44) vs ₹479.8 ± 335.0 ($5.78 ± 4.04/€5.28 ± 3.69) ( P = 0.001)]. The healthcare expenses incurred by inpatients were significantly higher than those of outpatients in the categories of medicines, diagnostics, and dietary provisions. Furthermore, it was observed that 76% of patients with psoriasis in the severe illness category and 13% in the mild-moderate group experienced catastrophic health expenditure. LIMITATIONS: The study underestimated costs by excluding comorbidities, productivity loss, indirect expenses, quality of life (QoL), private healthcare costs, and inflation adjustments. CONCLUSION: Patients with severe psoriasis experienced higher OOP expenses and catastrophic health expenditure. Financial aid from health agencies and the government could reduce costs and improve their QoL.

Authors

Institutions

Publication Details

Journal
Indian Dermatology Online Journal
Published
2026-04-22
DOI
https://doi.org/10.4103/idoj.idoj_172_25
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Out-of-Pocket Expenses in Patients with Psoriasis: A Study from a Tertiary Care Hospital in North India

Tarun K. Narang, Adhyatm Bhandari, Sanjeev Handa, Kavita Narang et al.
Indian Dermatology Online Journal
Psoriasis: Treatment and Pathogenesis
article

Out-of-Pocket Expenses in Patients with Psoriasis: A Study from a Tertiary Care Hospital in North India

Tarun K. Narang, Adhyatm Bhandari, Sanjeev Handa, Kavita Narang, Saurabh Narang, Sunil Dogra, Shankar Prinja
article en

Abstract

BACKGROUND: Chronic inflammatory skin diseases, like psoriasis, have a significant financial burden on patients. Developing countries could have a more severe impact due to low per capita income and low penetration of health insurance. AIM AND OBJECTIVES: To evaluate the out-of-pocket (OOP) expenses of psoriasis patients and compare them between mild-moderate cases and severe cases. PATIENTS AND METHODS: The study involved psoriasis patients who were categorized into two groups based on the disease severity. The OOP expenses were calculated for the past four weeks. Inpatient versus outpatient management costs were also compared. RESULTS: The mean monthly OOP expenditure on treatment was significantly higher for the severe disease group [₹7087 ± 9021 ($85.45 ± 108.77/€78.09 ± 99.40)] than for the mild-moderate group [₹1871 ± 2138 ($22.56 ± 25.78/€20.61 ± 23.55) ( P = 0.001)]. In the severe disease group, OOP expenditure was notably higher than the mild-moderate group, primarily for medicines [₹4622 ± 7134 ($55.73 ± 86.02/€50.93 ± 78.61) vs ₹657.7 ± 534.9 ($7.93 ± 6.45/€7.24 ± 5.89) ( P = 0.001)] and diagnostics [₹1235 ± 1492 ($14.89 ± 17.99/€13.60 ± 16.44) vs ₹479.8 ± 335.0 ($5.78 ± 4.04/€5.28 ± 3.69) ( P = 0.001)]. The healthcare expenses incurred by inpatients were significantly higher than those of outpatients in the categories of medicines, diagnostics, and dietary provisions. Furthermore, it was observed that 76% of patients with psoriasis in the severe illness category and 13% in the mild-moderate group experienced catastrophic health expenditure. LIMITATIONS: The study underestimated costs by excluding comorbidities, productivity loss, indirect expenses, quality of life (QoL), private healthcare costs, and inflation adjustments. CONCLUSION: Patients with severe psoriasis experienced higher OOP expenses and catastrophic health expenditure. Financial aid from health agencies and the government could reduce costs and improve their QoL.

Indian Dermatology Online JournalVol. 17(3)
Post Graduate Institute of Medical Education and Research (IN)
Openalex Percentile: Top 19%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.